

**Table S2. Proportion with hyperkalemia and hypokalemia and mean value of serum potassium, by cohort**

Study	N	% Hyperkalemia	% Hypokalemia	Potassium mean (SD)	% RAAS inhibitor use	% ACE inhibitor use	% ARB use	% Renin inhibitor use	% K sparing diuretics use	% Other diuretics use	% Loop diuretics use	% thiazide diuretics use	% Kayexalate use
<b>CKD Cohorts</b>													
AASK	1066	91 (9%)	92 (9%)	4.2 (0.6)	620 (59%)	611 (58%)	12 (1%)	NA	NA	NA	NA	NA	NA
BC CKD	11785	2463 (21%)	193 (2%)	4.6 (0.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA
CanPREDDICT	2052	396 (19%)	49 (2%)	4.6 (0.6)	1463 (71%)	871 (42%)	761 (37%)	8 (0%)	122 (6%)	1394 (68%)	917 (45%)	621 (30%)	113 (6%)
CCF	17498	1917 (11%)	621 (4%)	4.4 (0.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA
CKD-JAC	2640	594 (22%)	36 (1%)	4.6 (0.6)	2170 (82%)	726 (28%)	1967 (75%)	0 (0%)	156 (6%)	749 (28%)	638 (24%)	211 (8%)	14 (1%)
CRIB	373	70 (19%)	9 (2%)	4.6 (0.6)	133 (36%)	117 (31%)	16 (6%)	NA	NA	151 (40%)	NA	NA	NA
Geisinger CKD†	24417	2945 (12%)	555 (2%)	4.5 (0.5)	12072 (49%)	9084 (37%)	3326 (14%)	22 (0%)	1771 (7%)	11313 (46%)	5886 (24%)	6287 (26%)	55 (0%)
MASTERPLAN	670	89 (13%)	23 (3%)	4.4 (0.6)	545 (81%)	343 (51%)	254 (38%)	NA	24 (4%)	331 (49%)	119 (18%)	216 (32%)	NA
MDRD	830	85 (10%)	40 (5%)	4.4 (0.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA
Mt Sinai BioMe CKD†	3518	454 (13%)	128 (4%)	4.4 (0.8)	1740 (49%)	1151 (33%)	665 (19%)	8 (0%)	183 (5%)	1284 (36%)	493 (14%)	841 (24%)	144 (4%)
PSP-CKD	9405	1718 (18%)	105 (1%)	4.6 (0.5)	6064 (64%)	4450 (47%)	1844 (20%)	NA	523 (6%)	4197 (45%)	2306 (25%)	2013 (21%)	NA
RCAV	124843	12778 (10%)	3528 (3%)	4.4 (0.5)	56445 (45%)	46162 (37%)	11515 (9%)	9 (0%)	8051 (6%)	41031 (33%)	22212 (18%)	20864 (17%)	223 (0%)
RENAAL	1513	386 (26%)	22 (1%)	4.7 (0.6)	737 (49%)	737 (49%)		NA	NA	910 (60%)	NA	NA	NA
SCREAM CKD†	29383	1639 (6%)	1060 (4%)	4.3 (0.5)	13599 (46%)	7630 (26%)	6730 (23%)	NA	2462 (8%)	10426 (35%)	8932 (30%)	1702 (6%)	322 (1%)
SRR-CKD	2591	363 (14%)	85 (3%)	4.4 (0.6)	1003 (39%)	0 (0%)	1002 (39%)	1 (0%)	NA	1801 (70%)	NA	NA	NA
Sunnybrook	2965	361 (12%)	99 (3%)	4.4 (0.5)	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Subtotal</b>	<b>235549</b>	<b>26348 (11%)</b>	<b>6645 (3%)</b>	<b>4.4 (0.5)</b>	<b>97256 (48%)</b>	<b>72906 (36%)</b>	<b>28129 (14%)</b>	<b>48 (0%)</b>	<b>13316 (7%)</b>	<b>73587 (37%)</b>	<b>41503 (21%)</b>	<b>32755 (17%)</b>	<b>871 (0%)</b>

<b>General Population</b>														
Beijing	1530	168 (11%)	4 (0%)	4.5 (0.5)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
CIRCS	8034	146 (2%)	66 (1%)	4.2 (0.4)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Gubbio	1684	20 (1%)	36 (2%)	4.2 (0.4)	91 (5%)	91 (5%)	NA	NA	59 (4%)	109 (6%)	9 (1%)	100 (6%)	NA	NA
KHS	108185	1047 (1%)	653 (1%)	4.2 (0.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
MRC	11840	1081 (9%)	328 (3%)	4.4 (0.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NHANES	57208	405 (1%)	2340 (4%)	4.0 (0.3)	5983 (10%)	4325 (8%)	1730 (4%)	14 (0%)	1347 (2%)	5498 (10%)	1548 (3%)	4100 (7%)	NA	NA
PREVEND	7319	204 (3%)	47 (1%)	4.4 (0.7)	334 (5%)	289 (5%)	47 (1%)	NA	13 (0%)	203 (3%)	57 (1%)	150 (2%)	NA	NA
Rancho Bernardo	1484	45 (3%)	17 (1%)	4.3 (0.4)	NA	NA	NA	NA	4 (0%)	256 (17%)	57 (4%)	203 (14%)	NA	NA
TaiwanMJ	159268	1077 (1%)	2896 (2%)	4.1 (0.3)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Takahata	1923	102 (5%)	23 (1%)	4.3 (0.4)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Subtotal</b>	<b>358475</b>	<b>4295 (1%)</b>	<b>6410 (2%)</b>	<b>4.1 (0.5)</b>	<b>6408 (10%)</b>	<b>4705 (7%)</b>	<b>1777 (4%)</b>	<b>14 (0%)</b>	<b>1423 (2%)</b>	<b>6066 (9%)</b>	<b>1671 (3%)</b>	<b>4553 (7%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>
<b>High Risk Cohorts</b>														
ADVANCE	11033	843 (8%)	183 (2%)	4.4 (0.5)		4490 (43%)	566 (5%)	NA	NA	1536 (14%)	NA	1536 (14%)	NA	NA
Geisinger	64503	3727 (6%)	1298 (2%)	4.3 (0.4)	23817 (37%)	18824 (29%)	5434 (8%)	28 (0%)	2687 (4%)	18889 (29%)	7422 (12%)	12336 (19%)	51 (0%)	NA
Maccabi	246712	12681 (5%)	830 (0%)	4.4 (0.4)	67908 (28%)	45960 (19%)	23442 (10%)	7 (0%)	2518 (1%)	18829 (8%)	5184 (2%)	13841 (6%)	85 (0%)	NA
Mt Sinai BioMe	8044	519 (6%)	293 (4%)	4.3 (0.7)	3126 (39%)	2190 (27%)	1032 (13%)	10 (0%)	246 (3%)	2141 (27%)	602 (7%)	1604 (20%)	141 (2%)	NA
SCREAM	208611	2369 (1%)	7089 (3%)	4.1 (0.4)	51217 (25%)	29420 (14%)	23293 (11%)	1 (0%)	4652 (2%)	22516 (11%)	16036 (8%)	6702 (3%)	308 (0%)	NA
ZODIAC	1153	55 (5%)	7 (1%)	4.4 (0.4)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Subtotal</b>	<b>540056</b>	<b>20192 (4%)</b>	<b>9699 (2%)</b>	<b>4.3 (0.4)</b>	<b>151351 (28%)</b>	<b>101364 (19%)</b>	<b>53912 (10%)</b>	<b>46 (0%)</b>	<b>10136 (2%)</b>	<b>63911 (12%)</b>	<b>29342 (6%)</b>	<b>36019 (7%)</b>	<b>585 (0%)</b>	<b>585 (0%)</b>
<b>General population/ high risk subtotal</b>	<b>898531</b>	<b>24487 (3%)</b>	<b>16109 (2%)</b>	<b>4.2 (0.4)</b>	<b>157759 (26%)</b>	<b>106069 (18%)</b>	<b>55689 (9%)</b>	<b>60 (0%)</b>	<b>11559 (2%)</b>	<b>71173 (12%)</b>	<b>31013 (5%)</b>	<b>40572 (7%)</b>	<b>585 (0%)</b>	<b>585 (0%)</b>

<b>Total†</b>	<b>1076762</b>												
Hyperkalemia: Potassium >5 mmol/L Hypokalemia: Potassium <3.5 mmol/L † CKD population from three administrative high risk cohorts, not included in the total N													